Clasificación en acciones
#40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Precio por acción
$0.00323826
Última sincronización: 2026-08-12
Capitalización bursátil
$104.81K
Comercio Purple Biotech Ltd. (PPBT)
Ingresos de Purple Biotech Ltd. (PPBT)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Purple Biotech Ltd., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Purple Biotech Ltd. desde 2026 hasta 2026
Ingresos al final de cada año
| Año |
Ingresos |
Cambiar |
|
Not enough data for the provided dates. |
Ingresos de empresas similares o competidoras
| Empresa |
Ingresos |
Diferencia de ingresos |
País |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$10.11B |
-
|
BE
|
